ENTRY       D12195                      Drug
NAME        Izuralimab (USAN)
FORMULA     C5622H8636N1502O1738S38
EXACT_MASS  126214.2944
MOL_WEIGHT  126292.2158
SEQUENCE    (Chain A)
            EIVLTQSPAT LSASPGERVT LTCRASQSVG NDVAWYQQKP GQAPRLLINY ASHRYTGVPD
            RFTGSGYGTE FTLTISSVQS EDFGVYYCQQ DFSSPRTFGG GTKVEIKGKP GSGKPGSGKP
            GSGKPGSEVQ LVESGGGLVK PGGSLRLSCV ASGFTFSNYW MNWVRQAPGK GLEWVAEIRL
            YSNNYATHYA ESVKGRFTIS RDDSKSTLYL QMNNLKTEDT GVYYCTRYYG NYGGYFDVWG
            RGTLVTVSSE PKSSDKTHTC PPCPAPPVAG PSVFLFPPKP KDTLMISRTP EVTCVVVDVK
            HEDPEVKFNW YVDGVEVHNA KTKPREEQYN STYRVVSVLT VLHQDWLNGK EYKCKVSNKA
            	 LPAPIEKTIS KAKGQPREPQ VYTLPPSREQ MTKNQVKLTC LVKGFYPSDI
            AVEWESNGQP ENNYKTTPPV LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV LHEALHSHYT
            QKSLSLSPGK
            (Chain B)
            QVQLVQSGAE VKKPGASVKV SCKASGYTFT GYYMHWVRQA PGQGLEWMGW INPHSGGTNY
            AQKFQGRVTM TRDTSISTAY MELSRLRSDD TAVYYCARTY YYDSSGYYHD AFDIWGQGTM
            VTVSSASTKG PSVFPLAPSS KSTSGGTAA GCLVKDYFPE PVTVSWNSGA LTSGVHTFPA
            VLQSSGLYSL SSVVTVPSSS LGTQTYICNV NHKPSDTKVD KKVEPKSCDK THTCPPCPAP
            PVAGPSVFLF PPKPKDTLMI SRTPEVTCVV VDVKHEDPEV KFNWYVDGVE VHNAKTKPRE
            EEYNSTYRVV SVLTVLHQDW LNGKEYKCKV SNKALPAPIE KTISKAKGQP REPQVYTLPP
            SREEMTKNQV SLTCDVSGFY PSDIAVEWES DGQPENNYKT TPPVLDSDGS FFLYSKLTVD
            KSRWEQGDVF SCSVLHEALH SHYTQKSLSL SPGK
            (Chain C)
            DIQMTQSPSS VSASVGDRVT ITCRASQGIS RLLAWYQQKP GKAPKLLIYV ASSLQSGVPS
            RFSGSGSGTD FTLTISSLQP EDFATYYCQQ ANSFPWTFGQ GTKVEIKRTV AAPSVFIFPP
            SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
            LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
            (Disulfide bridge: A23-A88, A149-A225, A260-B234, A263-B237, A294-A354, A400-A458, B22-B96, B152-B208, B228-C214, B268-B328, B374-B432, C23-C88, C134-C194)
  TYPE      Peptide
CLASS       Antineoplastic
             DG02938  Immune checkpoint inhibitor
EFFICACY    Antineoplastic, Immunomodulator
  TYPE      Monoclonal antibody, bispecific antibody
TARGET      ICOS (CD278) [HSA:29851] [KO:K06713]
            PDCD1 (PD1, CD279) [HSA:5133] [KO:K06744]
  PATHWAY   hsa04514(29851+5133)  Cell adhesion molecules
            hsa04660(29851+5133)  T cell receptor signaling pathway
            hsa04672(29851)  Intestinal immune network for IgA production
            hsa05235(5133)  PD-L1 expression and PD-1 checkpoint pathway in cancer
BRITE       Drug groups [BR:br08330]
             Antineoplastic
              DG02938  Immune checkpoint inhibitor
               D12195  Izuralimab
            Target-based classification of drugs [BR:br08310]
             Cell surface molecules and ligands
              Other cell surface molecules
               Immune checkpoints
                PDCD1 (PD1, CD279)
                 D12195  Izuralimab (USAN)
               CD molecules
                ICOS (CD278)
                 D12195  Izuralimab (USAN)
DBLINKS     CAS: 2329669-80-7
///
